Nautilus Biotechnology, Inc. (NASDAQ:NAUT - Get Free Report)'s share price traded up 0.8% on Friday . The stock traded as high as $2.50 and last traded at $2.40. 108,352 shares were traded during mid-day trading, an increase of 37% from the average session volume of 79,021 shares. The stock had previously closed at $2.38.
Nautilus Biotechnology Price Performance
The firm has a market capitalization of $301.34 million, a price-to-earnings ratio of -4.29 and a beta of 1.23. The stock has a fifty day moving average of $2.70 and a two-hundred day moving average of $2.61.
Nautilus Biotechnology (NASDAQ:NAUT - Get Free Report) last issued its quarterly earnings results on Tuesday, October 29th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.04. During the same period last year, the firm posted ($0.13) earnings per share. On average, research analysts forecast that Nautilus Biotechnology, Inc. will post -0.57 EPS for the current year.
Insider Transactions at Nautilus Biotechnology
In other news, VP Mary E. Godwin sold 35,000 shares of Nautilus Biotechnology stock in a transaction dated Tuesday, September 17th. The stock was sold at an average price of $2.85, for a total value of $99,750.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 40.50% of the company's stock.
Institutional Investors Weigh In On Nautilus Biotechnology
Large investors have recently added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD grew its holdings in Nautilus Biotechnology by 35.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 16,078 shares of the company's stock worth $48,000 after purchasing an additional 4,239 shares during the period. SG Americas Securities LLC acquired a new stake in shares of Nautilus Biotechnology in the 3rd quarter valued at about $50,000. The Manufacturers Life Insurance Company bought a new stake in Nautilus Biotechnology in the 3rd quarter valued at about $67,000. China Universal Asset Management Co. Ltd. raised its stake in Nautilus Biotechnology by 63.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 24,121 shares of the company's stock worth $69,000 after buying an additional 9,404 shares during the period. Finally, MetLife Investment Management LLC bought a new position in Nautilus Biotechnology in the third quarter worth approximately $87,000. Institutional investors and hedge funds own 50.71% of the company's stock.
About Nautilus Biotechnology
(
Get Free Report)
Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.
Recommended Stories
Before you consider Nautilus Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nautilus Biotechnology wasn't on the list.
While Nautilus Biotechnology currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
